- Home
- SCYX vs RBOT Comparison
SCYX vs RBOT Comparison
Compare SCYX & RBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- RBOT
- Stock Information
- Founded
- SCYX 1999
- RBOT 2014
- Country
- SCYX United States
- RBOT United States
- Employees
- SCYX N/A
- RBOT N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- RBOT Medical Specialities
- Sector
- SCYX Health Care
- RBOT Health Care
- Exchange
- SCYX Nasdaq
- RBOT Nasdaq
- Market Cap
- SCYX 40.9M
- RBOT 33.9M
- IPO Year
- SCYX 2014
- RBOT N/A
- Fundamental
- Price
- SCYX $0.90
- RBOT $5.39
- Analyst Decision
- SCYX
- RBOT Hold
- Analyst Count
- SCYX 0
- RBOT 2
- Target Price
- SCYX N/A
- RBOT $9.25
- AVG Volume (30 Days)
- SCYX 94.5K
- RBOT 20.7K
- Earning Date
- SCYX 05-07-2025
- RBOT 04-28-2025
- Dividend Yield
- SCYX N/A
- RBOT N/A
- EPS Growth
- SCYX N/A
- RBOT N/A
- EPS
- SCYX N/A
- RBOT N/A
- Revenue
- SCYX $3,746,000.00
- RBOT N/A
- Revenue This Year
- SCYX $460.12
- RBOT N/A
- Revenue Next Year
- SCYX $253.87
- RBOT N/A
- P/E Ratio
- SCYX N/A
- RBOT N/A
- Revenue Growth
- SCYX N/A
- RBOT N/A
- 52 Week Low
- SCYX $0.73
- RBOT $4.27
- 52 Week High
- SCYX $3.07
- RBOT $19.00
- Technical
- Relative Strength Index (RSI)
- SCYX 45.97
- RBOT 33.03
- Support Level
- SCYX $0.89
- RBOT $5.07
- Resistance Level
- SCYX $0.99
- RBOT $5.95
- Average True Range (ATR)
- SCYX 0.08
- RBOT 0.57
- MACD
- SCYX 0.01
- RBOT 0.15
- Stochastic Oscillator
- SCYX 64.71
- RBOT 22.54
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.